Neuroimaging pioneer IXICO PLC (AIM:IXI, OTC:PHYOF) said it won a contract with an unnamed biotech worth around £800,000 to provide its expertise in assessing the progression of Huntington's Disease.
Specifically, it will support a global observational study to assess participants for the early detection of the condition using its artificial intelligence-led data analytics, machine learning techniques and TrialTracker platform.
Chief executive Giulio Cerroni said: "With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs.
“We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease.”